Regeneron Pharmaceuticals clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-08
What changed in the last 30 days
29 trials changed in the last 30 days: 0 stopped, 5 with notable changes, 24 with minor changes only.
- Minor: ACCESS-1 · How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works · Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment Trial completed
- Minor: LINKER-MM4 · Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works · Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment Enrollment closed, study ongoing
- Minor: AURA-AD · REGN20423 in Healthy Adult Participants and Adult · Atopic Dermatitis Primary and study completion pushed from Jun 23, 2028 to Aug 14, 2028
- Minor: Ubamatamab Combination Therapy · Platinum-Resistant Ovarian Cancer Enrollment increased: 297 → 397 participants
- Minor: ROXI-ASPEN · REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants Trial sites expanded: 49 → 57 locations
- Minor: ROXI-PALISADE · Reducing Adverse Vascular Outcomes With Factor XI Inhibition · Peripheral Artery Disease Trial sites expanded: 29 → 32 locations
- Minor: ROXI-CAT-I · REGN7508 in Adult Participants · Cancer-Associated Thrombosis Trial sites expanded: 23 → 28 locations
- Minor: ROXI-EVEREST · Stroke and Systemic Embolism Prevention · Atrial Fibrillation Trial sites expanded: 54 → 66 locations
- Minor: ROXI-ATLAS · Adult · Atrial Fibrillation Who Are Treated With Anticoagulation Trial sites expanded: 87 → 91 locations
- Minor: ALN-CIDEB · Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) Enrollment closed, study ongoing
- Minor: LINKER-MM5 · Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens · Relapsed/Refractory Multiple Myeloma (RRMM) Trial sites expanded: 44 → 53 locations
- Minor: LINKER-SMM2 · Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) Trial sites expanded: 27 → 33 locations
- Minor: Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab · Metastatic Castration-Resistant Prostate Cancer and Other Tumors Trial sites expanded: 24 → 27 locations
- Notable: Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments · Operable Non-Small Cell Lung Cancer (NSCLC) Primary completion pushed from May 20, 2027 to Dec 4, 2029
- Minor: Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD) Trial completed
- Notable: ALN-CIDEB · Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Recruitment opened
- Minor: CEMI-LUNG · Cemiplimab · Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe Enrollment closed, study ongoing
- Minor: Cemiplimab-based Treatments · Locally Advanced Basal Cell Skin Cancer (laBCC) Start date pushed from Oct 15, 2026 to Nov 13, 2026
- Notable: REGN17235 · Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation Recruitment opened
- Notable: ALN-CIDEB · Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Recruitment opened
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New trial filings, last 30 days
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-28 | NCT07901725 Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone… | Phase 3 | Not Yet Recruiting |
| 2026-10-26 | NCT07896265 Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes | Phase 3 | Not Yet Recruiting |
| 2026-10-21 | NCT07887750 REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or… | Phase 1/2 | Not Yet Recruiting |
| 2026-10-15 | NCT07876492 A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult… | Phase 3 | Not Yet Recruiting |
| 2026-10-15 | NCT07876505 Healthy Adult Participants Trial Comparing Different Cenvacibart Presentations | Phase 1 | Not Yet Recruiting |
Active trials by phase
| Phase 1 | 18 | |
| Phase 1/2 | 26 | |
| Phase 2 | 27 | |
| Phase 2/3 | 2 | |
| Phase 3 | 36 | |
| Phase 4 | 4 |
Not charted: 10 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Disease areas by active trials, top 10 of 39
Multiple Myeloma (12) · Lung Cancer (11) · Non-Small Cell Lung Cancer (NSCLC) (11) · Obesity (10) · Non-Hodgkin Lymphoma (8) · Melanoma (7) · NASH / MASH (6) · Prostate Cancer (5) · Chronic Kidney Disease (4) · Follicular Lymphoma (4)
Get alerts when Regeneron Pharmaceuticals's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.